Fischer R
Deutschen Gesellschaft für Berg- und Expeditionsmedizin, Medizinische Klinik Innenstadt, Universität München.
MMW Fortschr Med. 2004 Feb 19;146(8):33-4, 36-7.
At altitudes higher than the threshold altitude of 2,500 m, high-altitude diseases may occur, usually after a delay of 6 to 12 hours. Apart from the headache associated with acute mountain sickness, life-threatening cerebral edema may develop. High-altitude pulmonary edema is a non-cardiac edema that often precedes acute mountain sickness. The most important preventive measure is a slow ascent. In the case of mountain sickness a prophylactic effect can be achieved with acetazolamide or dexamethasone possible, while for high-altitude pulmonary edema, nifedipine is the first-choice drug. Immediate descent and the administration of oxygen are always indicated. Patients with a high-altitude risk are those with cardiac or pulmonary disease. Nevertheless, it is still possible for patients with coronary heart disease, hypertension or bronchial asthma to attain to high altitudes. In contrast, patients with COPD, interstitial pulmonary disease or pulmonary hypertension are at appreciably greater risk.
在高于2500米的阈值海拔高度时,通常在延迟6至12小时后可能会发生高原病。除了与急性高山病相关的头痛外,还可能发展为危及生命的脑水肿。高原肺水肿是一种非心源性水肿,通常先于急性高山病出现。最重要的预防措施是缓慢上升。对于高山病,乙酰唑胺或地塞米松可能具有预防作用,而对于高原肺水肿,硝苯地平是首选药物。始终建议立即下降并给予氧气。有高原病风险的患者是患有心脏或肺部疾病的人。然而,冠心病、高血压或支气管哮喘患者仍有可能到达高海拔地区。相比之下,慢性阻塞性肺疾病、间质性肺疾病或肺动脉高压患者的风险明显更高。